AnaCardio is a clinical stage company developing novel drugs to treat heart failure. The company was founded based on ground-breaking research from Karolinska Institute (Sweden) showing improved contractility of the heart muscle through a unique and differentiated mechanism.
The mode of action is novel and orthogonal to standard of care in patients with heart failure with reduced ejection fraction.
Sound Contact: Johan Kördel (Board Director) and Philip Brainin (Board observer)
Read an interview with CEO, Patrik Strömberg: Applying the best of both science and business to treat heart failure
AnaCardio
AC01
Heart Failure
Progress
